Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase <scp>II</scp> , Randomized, <scp>Double‐Blind</scp> , <scp>Placebo‐Controlled Dose‐Ranging</scp> Trial

Subjects

Subjects :

Rheumatology

Details

ISSN :

25785745

Volume :

5

Database :

OpenAIRE

Journal :

ACR Open Rheumatology

Accession number :

edsair.doi...........9b9466da0aa9a79b3ec812df5812e5ab